CompletedNot Applicable

Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2

United States15 participantsStarted 2015-03

Plain-language summary

The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prevent heparin use in people who will get HIT.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18 years of age or older * Ability to give informed consent * Participants with heparin/PF4 antibody and SRA testing for HIT, including: participants with negative heparin/PF4 antibodies and negative SRA (controls), participants with positive heparin/PF4 antibodies and negative SRA (seroconversion cases), and participants with positive heparin/PF4 antibodies and positive SRA (HIT cases) * Treatment with unfractionated heparin or low molecular weight heparin (enoxaparin, dalteparin, tinzaparin) within 7 days of blood draw Exclusion Criteria: * Less than 18 years of age * Inability to give informed consent

What they're measuring

Serotonin Release Assay

Timeframe: 0-30 days

Heparin/platelet factor 4 antibody

Timeframe: 0-30 days

Trial details

NCT IDNCT02526485

SponsorVanderbilt University Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-09-05

View on ClinicalTrials.gov More Heparin-induced Thrombocytopenia trials